Expert witnesses
General vs specific causation: which experts does a drug or toxic exposure case need?
In a drug or toxic exposure case the plaintiff proves causation twice. General causation asks whether the substance can cause this kind of injury in people at all. Specific causation asks whether it caused this plaintiff's injury. The first answer usually comes from an epidemiologist or toxicologist, the second from a physician, and courts have excluded experts who skipped either step or bridged them with assumptions.

What is the difference between general and specific causation?
General causation is whether a substance is capable of causing a particular injury in the general population. Specific causation is whether the substance caused a particular individual's injury. The plaintiff carries the burden on both.
Judge Milazzo of the Eastern District of Louisiana stated the two questions in an order of February 12, 2021 in the Taxotere (docetaxel) multidistrict litigation, MDL No. 2740: "General causation is whether a substance is capable of causing a particular injury or condition in the general population, while specific causation is whether a substance caused a particular individual's injury."
The Eleventh Circuit used similar words in McClain v. Metabolife International, Inc., decided March 2, 2005. "General causation is concerned with whether an agent increases the incidence of disease in a group," while individual causation asks whether the plaintiff was exposed to enough of the toxin to cause the alleged injury.
The order of the questions matters. A plaintiff who cannot show that a drug can cause the injury in anyone has no specific causation question left.
Why does a causation case usually need more than one expert?
The two questions call for different science. General causation rests on epidemiology, toxicology and exposure science; specific causation rests on the plaintiff's medical records, exposure history and a differential diagnosis by a physician.
The Reference Manual on Scientific Evidence, Fourth Edition, published by the Federal Judicial Center and the National Academies of Sciences, Engineering, and Medicine with a date line of December 31, 2025, groups the relevant science in four reference guides: Exposure Science and Exposure Assessment (pages 833 to 898 in the book's pagination), Epidemiology (899 to 1028), Toxicology (1029 to 1106) and Medical Testimony (1107 to 1186). A short prologue introduces the first three together.
Each guide matches a task in the case. The exposure scientist estimates how much of the substance the plaintiff took in and for how long. The epidemiologist reads the human studies for an association between the substance and the disease. The toxicologist addresses mechanism and dose. The physician applies all of that to the plaintiff's own records and rules out other causes of the injury.
In McClain the plaintiffs' causation case rested on two witnesses, James O'Donnell, a doctor of pharmacy, and Hashim Hakim, a physician. The court examines each opinion against the qualifications and the data behind it, so a physician who offers a general causation opinion has to show the epidemiological basis for it.
What does a general causation expert have to show?
First a statistically significant association between the substance and the disease, then that a true causal relationship underlies the association, usually through the Bradford Hill criteria. Dose is part of both steps.
The Taxotere order described a two-step test. There must first be "a statistically significant association" between the agent and the disease. Researchers then assess whether "a true causal relationship underlies the association," and experts typically apply the Bradford Hill criteria to that second step.
McClain added dose. The Eleventh Circuit wrote that "the relationship between dose and effect (dose-response relationship) is the hallmark of basic toxicology" and that "Dose is the single most important factor to consider." It also said that for many substances "there is some dose below which even repeated, long-term exposure would not cause an effect in any individual." A general causation opinion that does not say at what dose the substance causes the injury leaves the specific causation expert with nothing to compare the plaintiff's exposure against.
The same court addressed background risk: "The background risk is not the risk posed by the chemical or drug at issue in the case," and "A reliable methodology should take into account the background risk." Strokes, heart attacks and cancers occur in people who never took the drug, and the expert has to account for them.
What did the Supreme Court decide in GE v. Joiner?
That a trial court may exclude a causation opinion when the studies behind it do not fit the facts. The Court upheld exclusion of experts who linked PCBs to lung cancer through mouse studies and unsupportive epidemiology.
General Electric Co. v. Joiner was decided on December 15, 1997, in an opinion by Chief Justice Rehnquist. Robert Joiner worked from 1973 as an electrician in the Water & Light Department of Thomasville, Georgia, on transformers cooled with a mineral-based dielectric fluid. In 1983 the city found that some of the fluid was contaminated with PCBs. Joiner was diagnosed with small cell lung cancer in 1991 and claimed that PCBs and their derivatives, furans and dioxins, promoted it. He had smoked for about eight years, both his parents smoked, and his family had a history of lung cancer.
His experts relied on studies of infant mice given massive, highly concentrated doses of PCBs injected into the peritoneum or the stomach; the mice developed alveologenic adenomas. They also relied on four epidemiological studies. In the Italian capacitor plant study the authors saw no grounds to link the lung cancer deaths to exposure. The Monsanto plant study found an increase that was not statistically significant. The Norwegian cable company study found an increase among workers exposed to mineral oil and did not mention PCBs. The Japanese Yusho study involved people exposed to many carcinogens, including toxic rice oil they ingested.
The Court called the animal studies "so dissimilar to the facts presented in this litigation" and wrote: "nothing in either Daubert or the Federal Rules of Evidence requires a district court to admit opinion evidence which is connected to existing data only by the ipse dixit of the expert. A court may conclude that there is simply too great an analytical gap between the data and the opinion proffered." It held that abuse of discretion is the standard for reviewing a decision to admit or exclude scientific evidence. The question of exposure to furans and dioxins was left open.
When is general causation itself the disputed question?
When the medical community does not generally recognize the substance as causing the injury. In McClain the Eleventh Circuit put an ephedrine and caffeine product in that category and found the experts' proof short.
McClain v. Metabolife International, Inc. involved Metabolife 356, an herbal appetite suppressant containing ephedrine and caffeine. Three plaintiffs suffered ischemic strokes and one a heart attack. The court separated toxic tort cases into those where the medical community generally recognizes the agent as toxic and as causing the type of harm, and "those cases in which the medical community does not generally recognize the agent as both toxic and causing the injury plaintiff alleges." It placed the case in the second group.
In the second group general causation needs its own reliable proof, and the court found the plaintiffs' experts, a pharmacist and a physician, short of it. It wrote that "case reports raise questions; they do not answer them." It rejected reliance on regulatory action, noting that "The FDA will remove drugs from the marketplace upon a lesser showing of harm to the public" and that "risk-utility analysis involves a much lower standard than that which is demanded by a court of law." It called an analogy between ephedrine and another drug, phenylpropanolamine, "a leap of faith."
The court concluded that "Plaintiffs' experts took leaps of faith and substituted their own ipse dixit for scientific proof on essential points," held that the trial court abused its discretion by abdicating its gatekeeper role, and reversed and remanded.
Does the plaintiff need studies showing a doubled risk?
In Texas, when causation rests on epidemiology, yes. The Supreme Court of Texas requires a statistically significant doubling of the risk in at least two properly designed studies of people similar to the plaintiff.
The Texas rule comes from Merrell Dow Pharmaceuticals, Inc. v. Havner (1997). The Supreme Court of Texas applied it to Vioxx in Merck & Co. v. Garza, decided August 26, 2011, in an opinion by Justice Hecht. Under Havner, as the court restated it, a threshold requirement of reliability is evidence of "a statistically significant doubling of the risk," "statistically significant at the 95% confidence level," and the standards must be met "in at least two properly designed studies." The plaintiff must also "show that he or she is similar to" the subjects of the studies, whose conditions "should be substantially similar to the claimant's circumstances." The court held that these requirements apply to all epidemiological evidence, clinical trials included.
Leonel Garza was 71 and had a long history of heart disease, including a prior heart attack, bypass surgery and a stent. He took 25 mg Vioxx tablets, a week's supply and then thirty more, and died on April 21, 2001 of a probable heart attack. The VIGOR study his family relied on "involved a dosage of 50 mg and a median duration of 9 months," twice his dose and far longer than his use. The APPROVe trial "did not show statistically significant differences until after eighteen months." The court refused to extrapolate from higher doses and longer durations, held the evidence legally insufficient on general causation and rendered judgment that the family take nothing.
Garza shows how the dose and duration in the studies become a specific causation problem. The general causation expert has to find studies at the plaintiff's dose and duration, or the specific causation expert has no studies that apply to the plaintiff.
What does a specific causation expert have to show?
That the plaintiff was exposed to enough of the substance, that the timing fits, and that other plausible causes were ruled out, usually through a differential diagnosis based on the records and an examination.
McClain framed the individual question as whether the plaintiff was "exposed to enough of the toxin to cause the alleged injury." Garza added the other half: the plaintiff must exclude "other plausible causes of the injury or condition that could be negated." For a 71-year-old with a prior heart attack and bypass surgery, those other causes were the plaintiff's own heart disease.
The usual method is differential diagnosis, also called differential etiology: list the possible causes of the injury, then rule them out one by one with evidence from the records. In the Taxotere order the defense dermatopathologist, Dr. Mamina Turegano, opined that chemotherapy did not contribute to the plaintiff's alopecia. Her method included a literature review, an examination of the plaintiff and a review of her medical records. The court found that she "appears to have conducted a differential diagnosis, although the Court finds that this analysis is less than clear," and that she did not explicitly rule out other forms of alopecia she discussed.
The court denied the motion to exclude her and left the weaknesses to deposition and trial. It cited the principle that "Vigorous cross-examination, presentation of contrary evidence, and careful instruction on the burden of proof" are the means of attacking "shaky but admissible evidence." A differential diagnosis that lists causes without explaining how each was excluded therefore may survive a motion and still lose in front of the jury.
Does a defense causation expert have to prove general causation too?
No. Because the plaintiff carries the burden on both questions, the Taxotere court held that a defense expert need not conduct a general causation analysis before opining that the drug did not cause this plaintiff's injury.
The plaintiff in the Taxotere order, Elizabeth Kahn, challenged Dr. Turegano partly on the ground that she offered a specific causation opinion without a general causation analysis. The court rejected the argument: Dr. Turegano "need not conduct a general causation analysis" because the plaintiff bears the burden on both general and specific causation.
The court also held that the report complied with Rule 26 and described the method adequately. It read the report as stating that the chemotherapy "did not contribute to her alopecia" and found the deposition testimony the plaintiff cited unpersuasive on that point.
For a defense team the practical consequence is a choice of targets. The defense can attack the plaintiff's general causation evidence, as the defendants did in Joiner and Garza, or the individual case, with a physician who points to another cause, as in the Taxotere order.
How does IAE find causation experts for a drug or toxic exposure case?
The request names the field directly: epidemiology, toxicology, exposure science or the clinical specialty of the injury. Within 1 business day IAE replies whether it can search in that field by the disclosure deadline.
The request form for an expert witness in a product liability case has a free-text field for the expertise needed, next to the case type, the state and court, the firm's side, the expert disclosure deadline and the parties with their counsel. In a causation case the firm can list both experts it needs and describe the substance, the dose and duration of exposure and the injury. The form asks not to include privileged or sealed information.
Within 1 business day IAE replies whether it can search in that field by the deadline. Each candidate confirms in writing that he or she has no ties to the parties or their counsel. Within 5 business days the firm receives 2-3 candidates with CVs, hourly rates, testimony in the last 4 years and publications in the last 10 years, the lists that Rule 26(a)(2)(B) requires.
Candidate names and CVs come after the $2,000 search fee is paid in advance. If no candidate fits, the second search is free, and if IAE finds no candidates, it refunds the fee. The expert bills the firm directly or through IAE under the agency option. The expert's hourly rate never depends on the outcome of the case or on the content of testimony. IAE is not a law firm; case strategy and the decision to retain an expert stay with the attorney.
Sources
- General Electric Co. v. Joiner, 522 U.S. 136 (1997) (LII, Cornell Law School)
- McClain v. Metabolife International, Inc., No. 03-12776 (11th Cir. Mar. 2, 2005)
- Merck & Co. v. Garza, No. 09-0073 (Tex. Aug. 26, 2011) (Justia)
- In re Taxotere (Docetaxel) Products Liability Litigation, MDL No. 16-2740, Order and Reasons on Dr. Mamina Turegano (E.D. La. Feb. 12, 2021)
- Reference Manual on Scientific Evidence, Fourth Edition (Federal Judicial Center)
- Reference Manual on Scientific Evidence: Fourth Edition (2025), contents (National Academies Press)
Read also
All articles
State of the art defense in product liability: what must the manufacturer's expert prove about the technology available when the product was made?
The state of the art defense asks what a manufacturer could have known and built on the day the product left its hands, not on the day of the injury
Toy injury expert witness: small parts, age grading and ASTM F963 in a children's product case
A toy injury case usually turns on a short list of questions: was the toy meant for a child under three, did any part fit inside the federal small
Machine guarding expert witness: what does the engineer examine when a worker is hurt by an unguarded machine?
When a worker is hurt at the point of operation of a machine, the case usually turns on the guard: how the machine was designed to keep hands outExpert witnesses
Need an expert witness for your case?
Describe the question, the case type and the court. Within 5 business days you receive 2-3 candidates with CVs, hourly rates and lists of prior testimony.

